Eli Lilly and Co. stock at EUR 1,276.60, up 0.60% premarket
Published on 11/11/2026 at 08:10 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat Matters Before The Open
- Late-stage Foundayo results support Lilly's plan to seek U.S. approval for an obstructive sleep-apnea indication by year-end.
- The obesity franchise remains central to Lilly's growth outlook and competitive position against Novo Nordisk.
Eli Lilly and Co. stock traded at EUR 1,276.60 on Lang & Schwarz at 08:09 CET on Wednesday, November 11, 2026, 0.60 percent above the Xetra close of Tuesday, November 10, 2026 at EUR 1,269.00.
The premarket indication comes as investors assess new clinical evidence for Lilly's obesity portfolio. CNBC reported that late-stage Foundayo results reduced the severity of obstructive sleep apnea in adults with obesity. Lilly plans to seek U.S. approval for that use by the end of 2026.
An expanded indication could broaden the commercial reach of the daily obesity pill and strengthen Lilly's position in the growing oral GLP-1 market. The company is competing with Novo Nordisk as both drugmakers build broader obesity-treatment franchises.
The FDA has also called for new warnings on certain GLP-1 medicines over a rare serious eye risk. The warning applies across the drug class and does not identify a Lilly-specific change in product safety, according to the CNBC report.
Broader sentiment can be tracked through the S&P 500.
